Abstract:Abstract Abstract 4080 Phosphatidylinositol 3-kinase (PI3K) plays a central role in cell metabolism. PI3K is activated by growth factors, cytokines, and other stimulatory factors in association with their receptors. Activated PI3K in turn initiates signaling transduction to Akt-mTOR and leads to regulation of cell growth, proliferation, and apoptosis. Dysregulation of the pathway is widely seen in different types of human cancers, including multiple myeloma (MM). Therefore, PI3K-Akt inhibition is expected to exert broad anti-MM activity. Compound A (CA) is a novel pan-PI3K inhibitor, developed by Novartis Oncology. This compound has shown significant cell growth inhibition and induction of apoptosis in a variety of tumor cell lines. CA is currently being investigated in Phase I clinical trials in solid tumor patients. In this study, we investigated the in vitro and in vivo anti-MM activity of CA. Our findings showed that CA induces apoptosis in MM cell lines, ARP1, ARK, MM.1S, MM.1R, CAG and U266, and primary MM cells in both a time-dependent and a dose-dependent manner in vitro. Western blot analysis indicated activation of caspases after CA exposure. The presence of MM bone marrow stromal cells (BMSCs) or addition of IL-6, the growth cytokine for MM, did not attenuate CA-induced MM cell apoptosis. More importantly, CA only showed limited cytotoxicity toward normal lymphocytes or non-tumoric BMSCs. Results from mechanistic studies showed that CA treatment results in cell cycle arrest in G1 phase by upregulating cell cycle repressor p27 (Kip1) and downregulating cyclin D1. CA treatment also caused decreased anti-apoptotic XIAP expression, and increased cytotoxic small isoform of Bim, BimS expression, both of which may contribute to CA-induced cell apoptosis. In addition to its effect in vitro, CA showed potent anti-MM activity in vivo in an established MM model in SCID mice. CA treatment repressed tumor growth and prolonged the survival of tumor-bearing mice. To test the synergistic/addictive effect of CA with other MM chemotherapeutics, we combined CA with melphalan, dexamethasone, lenalidomide, or bortezomib to treat MM cells. Our results showed that low doses of CA and dexamethasone, either of which alone has only limited cytotoxicity, exhibited synergistic anti-MM activity in dexamethasone-sensitive cell lines ARP1 and MM.1S, but not in dexamethasone-resistant cell MM.1R. Western blot analysis suggested that CA and dexamethasone combined treatment in MM.1S results in accumulation of the cytotoxic BimS. Increased BimS expression may cause the synergistic effect of CA and dexamethasone. Thus, our findings suggest CA alone or together with dexamethasone may be a promising treatment for MM. Disclosures: No relevant conflicts of interest to declare.

Platycodin D Inhibits Proliferation, Migration and Induces Chemosensitization Through Inactivation of the NF‐κB and JAK2/STAT3 Pathways in Multiple Myeloma Cells

Blockade of PLD1 Potentiates the Antitumor Effects of Bortezomib in Multiple Myeloma Cells by Inhibiting the Mtor/nf-Κb Signal Pathway

Polyphyllin I Induces Cell Cycle Arrest and Apoptosis in Human Myeloma Cells Via Modulating Β‐catenin Signaling Pathway

Inhibitory Effect of Platycodin D on Human Colonic Cancer SW620 Cell Proliferation

Platycodin D induces proliferation inhibition and mitochondrial apoptosis in diffuse large B-cell lymphoma

Triptolide Enhances the Sensitivity of Multiple Myeloma Cells to Dexamethasone Via Micrornas.

Platycodin D induces apoptotic cell death through PI3K/AKT and MAPK/ERK pathways and synergizes with venetoclax in acute myeloid leukemia

Platycodin D, a Metabolite of Platycodin Grandiflorum, Inhibits Highly Metastatic MDA-MB-231 Breast Cancer Growth in Vitro and in Vivo by Targeting the MDM2 Oncogene.

DCZ0801, a Novel Compound, Induces Cell Apoptosis and Cell Cycle Arrest Via MAPK Pathway in Multiple Myeloma.

Triptolide Overcomes Dexamethasone Resistance and Enhanced PS-341-induced Apoptosis Via PI3k/Akt/NF-kappaB Pathways in Human Multiple Myeloma Cells.

Platycodin D Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma Cells Through Regulation of Skp2

Novel Pi3k Inhibitor Compound A Induces Myeloma Cell Apoptosis And Shows Synergistic Cytotoxicity With Dexamethasone In Multiple Myeloma

Dual Inhibition of Mtorc1/2 by DCZ0358 Induces Cytotoxicity in Multiple Myeloma and Overcomes the Protective Effect of the Bone Marrow Microenvironment

Daptomycin Inhibits Multiple Myeloma Progression through Downregulating the Expression of RPS19

A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells

Platycodin D reduces PD‐L1 levels by inhibiting LXR‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells

A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory

A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway

Platycodin D Inhibits Tumor Growth by Antiangiogenic Activity Via Blocking VEGFR2-mediated Signaling Pathway

RhPDCD5 Combined with Dexamethasone Increases Antitumor Activity in Multiple Myeloma Partially Via Inhibiting the Wnt Signalling Pathway

The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway